In a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer, Kisqali + ET confirmed nearly one year of additional overall survival (OS) benefit.
This subgroup analysis found that patients with visceral metastases—including liver metastases and multiple metastatic sites, treated with Kisqali (ribociclib) plus ET in the first-line setting, achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
Those with liver metastases on Kisqali plus endocrine therapy in the first line achieved 44.2 months median OS compared to 38.1 months for those on endocrine therapy alone.
First-line treatment with Kisqali-endocrine therapy achieved 57.7 months median OS compared to 49.3 months for those on endocrine therapy alone for patients with visceral metastases in three or more organs.
Price Action: NVS shares are up 2.13% at $82.99 during the premarket session on the last check Friday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
